Nevakar Inc.
  • Home
  • comp001
    • comp001b
  • comp002
  • Nevakar
  • NevakarInjectables
  • Vyluma
Select Page

Nevakar Injectables Announces the Launch of Ready-to-Use Ephedrine Injection Vials

by @dministrator | Mar 28, 2022 | NevakarInjectables

Bridgewater, NJ, USA, March 28, 2022 – Nevakar Injectables Inc., a biopharmaceutical company developing multiple sterile injectable products for use in the critical and ambulatory care settings, announced today the launch of its ready-to-use Ephedrine Sulfate...

Nevakar Announces Closing of $12 Million Convertible Note and Extension of Interest- Only Period with Oxford Finance

by @dministrator | Mar 9, 2022 | NevakarInjectables

Bridgewater, NJ, USA, March 9, 2022 – Nevakar Inc. (“Nevakar”), a biopharmaceutical company developing multiple assets in the ophthalmic and injectable areas, announced today that it has closed on $12 million in convertible notes with both existing and new investors....

NEVAKAR INC. ANNOUNCES FORMATION OF NEVAKAR INJECTABLES

by @dministrator | May 25, 2021 | NevakarInjectables

Bridgewater, NJ (May 25, 2021) – Nevakar Inc. (“Nevakar”), a privately held biopharmaceutical company, today announces the establishment of Nevakar Injectables Inc., a newly formed company with an established portfolio of products focused on critical patient care,...

Industry Focus: A Look at Nevakar

by @dministrator | Mar 1, 2021 | NevakarInjectables

By JASON J. NICHOLS, OD, MPH, PHD View the article | CLICK HERE Dr. Puri, please tell us about your company in terms of its history and direction…

Nevakar Announces FDA Approval for Ephedrine Sulfate Injection as Ready-to-Use Vials

by @dministrator | Oct 22, 2020 | NevakarInjectables

Bridgewater, NJ, October 22, 2020 – Nevakar Inc., a biopharmaceutical company developing multiple assets in the ophthalmic and injectable areas, announced today it received approval from the U.S. Food and Drug Administration (FDA) to market Ephedrine Sulfate Injection...

American Society of Hospital Pharmacists Midyear (ASHP)

by @dministrator | Aug 24, 2020 | NevakarInjectables

December 8, 2019 – December 12, 2019
« Older Entries

Recent Posts

  • Nevakar Injectables Announces the Launch of Ready-to-Use Ephedrine Injection Vials
  • Nevakar Announces Closing of $12 Million Convertible Note and Extension of Interest- Only Period with Oxford Finance
  • Nevakar Announces Closing of $12 Million Convertible Note and Extension of Interest- Only Period with Oxford Finance
  • VYLUMA AND MYMYOPIA.COM SUPPORT 2021 WORLD SIGHT DAY TO RAISE AWARENESS OF VISION DISORDERS
  • VYLUMA INC LAUNCHES WITH ROBUST OPHTHALMIC PORTFOLIO, LEADING WITH A PHARMACEUTICAL TREATMENT IN PHASE III FOR MYOPIA

Recent Comments

    Archives

    • March 2022
    • October 2021
    • May 2021
    • March 2021
    • January 2021
    • November 2020
    • October 2020
    • August 2020
    • May 2020
    • November 2019
    • October 2019
    • September 2019
    • June 2019
    • August 2018
    • November 2017
    • June 2017
    • July 2016
    • June 2015

    Categories

    • NevakarInjectables
    • Vyluma

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • Facebook
    • Twitter
    • Google
    • Instagram
    • RSS

    Designed by Elegant Themes | Powered by WordPress